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Abstract 
 
Introduction: Extended half‐life (EHL) clotting factors have been shown to offer people with 
haemophilia (PwH) protection from bleeding with fewer infusions, which might reduce 
treatment burden. 
 
Aim: The HOw Patients view Extended half‐life products (HOPE) study aimed to explore, 
understand and describe patient expectations around the prophylactic use of EHL products 
and to establish whether these expectations were met through individual follow‐up 
analysis. 
 
Methods: The HOPE study was a prospective, qualitative cohort study conducted among 
PwH who had switched to Fc fusion protein EHL products in routine clinical care and who 
had not been recruited to clinical trials of these products. Semi‐structured audio‐recorded 
interviews were undertaken over two time points; transcripts were analysed to 
systematically generate theory from data that contains both inductive and deductive 
thinking. 
 
Results: Forty‐three interviews were conducted with 25 participants. Most participants were 
positive about EHL treatment and intended to continue using them. Reduced frequency of 
infusions meant lives were less disrupted or dominated by haemophilia, and there was less 
perceived stress on overused veins. For those PwH who did not reduce infusion frequency, 
there were other perceived benefits from EHLs with respect to greater protection with 
higher trough levels and fewer bleeds. 
 
Conclusion: Patients switching to EHL treatments believe these products will result in fewer 
infusions and less disruption of everyday life, leaving them feeling more protected with 
fewer bleeds and increased activity levels, as well as enhanced well‐being and mental 
health. Understanding patient expectation and experience around using products adds real‐
world data to clinical trial experience. 
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1   INTRODUCTION 
 
 
 
Extended half‐life (EHL) clotting factors may offer people with haemophilia (PwH) protection 
from bleeding with fewer infusions, which might reduce treatment burden.1,2 While patient 
expectation is high (as suggested by posts on social media), there are potential risks that 
PwH may forget to perform less regular infusions and thus experience more bleeds than 
currently. The HOw Patients view Extended half‐ life products (HOPE) study aimed to 
provide in depth qualitative data on the expectations of PwH about EHL products, and 
whether those expectations were met. The study was timed to start as EHL factors became 
commercially available in the UK (summer/autumn 2016). 
 
Clinical trials have demonstrated the efficacy of EHL products,3‐6 but little is known about 
why PwH would choose to switch to a new therapy. Understanding the rationale for 
switching from standard to EHL factor is an important aspect of haemophilia care. 
 
The HOPE study was designed to capture the expectations and the realities of PwH in the UK 
switching or recently switched to EHL factors, who had not been recruited to clinical trials of 
these products. The working hypothesis was that PwH would be keen to use these products 
and that for most, if not all, the promise of improved care would be met. 
 
The primary objective was to explore, understand and describe patient expectations around 
the prophylactic use of EHL products and to establish whether these expectations were met 
through individual follow‐up analysis. In addition, we sought to understand how patients 
used these products in everyday life. 
 
 
 
2   MATERIALS AND METHODS  
 
 
 
The HOPE study was a prospective, qualitative cohort study conducted among PwH who had 
switched to Fc fusion protein EHL products (subsequently EHL only) outside of clinical trials. 
The aim was to determine hopes and expectations of switching; and participants were 
recruited be‐ fore or as they switched products. Eligible participants were adults aged 
 
>16 years or parents of children aged <16 years with moderate or severe haemophilia A or B 
currently on prophylaxis with standard half‐life products who were likely candidates to be 
prescribed EHL coagulation factors as prophylaxis, and who were receiving treatment in a 
UK haemophilia centre. Sixteen is the legal age at which young people are deemed to have 
capacity and can consent to treatment by the National Health Service without parental 
consent. Patients prescribed EHL clotting factor products in a clinical trial setting and non‐
English speakers were excluded. 
 
The study was registered (Registration Number 2049) as a Clinical Audit/Service Evaluation 
project with the Clinical Governance and Safety Team at the lead site, which advised that it 
did not require approval from a local research ethics committee. This advice was echoed by 
other centres. Furthermore, the Kings Fund Experience Based Co‐Design Toolkit7 states that 
as this study will not change clinical practice, it is deemed not necessary to obtain research 
ethics approval. Nevertheless, study participants were required to verbally consent to be in 
the study. This consent could be withdrawn at any stage and would not impact upon their 
haemophilia care; as such, consent was reaffirmed before the second interview. 
 
The HOPE study was advertised via waiting room flyers in the investigators’ centres, 
additionally ‘switching’ patients were identified by clinical staff in centres as potential study 
participants and were given information about study participation. Participants contacted 
the research team by telephone or email to arrange an interview. Participants were also 
recruited via social media; the project was advertised via a flyer on UK haemophilia‐specific 
sites on Facebook. The HOPE study used a qualitative research design of semi‐ structured 
interviews with a longitudinal element using thematic analysis to systematically generate 
theory from data that contains both inductive and deductive thinking to formulate 
hypotheses that aim to discover participants’ views. The question the researcher repeatedly 
asks is ‘What's going on?’.8 Usually this is done in face‐ to‐face encounters; however, it has 
also been used with telephone interviews.9 We undertook a series of semi‐structured 
interviews in phase one (P1). We then made a further approach to each participant for a 
phase 2 (P2) interview at least 6 months later, looking for consistency with and changes 
from their earlier comments. 
 
The study coordinators and a patient co‐researcher developed the P1 interview schedule. 
The P2 interview schedule was based   on P1 and included issues that had emerged in P1. P2 
attempted   to capture change from the baseline of P1 in certain respects and to understand 
the experiences (or ‘journey’) from P1 to P2. This approach gives a very rich data set 
reflecting real‐life experiences of participants. The same researcher undertook all 
interviews. 
 
Interviews varied in duration from 15 to 30 minutes and were digitally recorded and 
transcribed verbatim by a professional transcriptionist unknown to the study participants to 
maintain anonymity. The transcripts were analysed using NVIVO qualitative data analysis 
software. Participants were anonymized and known by study number only. 
 
 
 
2.1   Data analysis 
 
Descriptive statistics were extracted from the qualitative data on name of treatment 
product used at P1 and P2, length of time on EHL, participant age, haemophilia type and 
severity and inhibitor status. These statistics were analysed using SPSS software (v.22). 
 
Data were coded line by line in each interview using NVIVO soft‐ ware (v.11) and then 
analysed using inductive thematic analysis,10 which identifies recurring patterns in the data. 
Ideas, comments or statements that recurred were organized into a hierarchical pattern of 
themes. Codes and themes were reviewed and refined through‐ out the analysis process. 
 
 
 
  
3   RESULTS 
 
 
 
3.1   Patient characteristics 
 
A total of 43 interviews were conducted with 25 people. Patient disposition is summarized 
in Figure 1. The first wave of interviews was conducted with PwH (or their parents) who 
were about to start, or had recently started, treatment with an EHL factor. In all, there were 
22 phase 1 interviews. These participants (subject to their con‐ sent) were then followed up 
approximately 6 months later when a P2 interview was conducted. At P2, three participants 
declined to be interviewed and one was withdrawn from the study following recruitment 
into a clinical trial. There were therefore 18 pairs of P1/P2 interviews. Three new 
participants were interviewed for the first time at P2; therefore, seven people provided one 
interview (four P1 and three P2). 
 
Table 1 summarizes the characteristics of each participant. Participants were either adults 
or parents of children with haemophilia (CwH). Two‐thirds of the interviews (67%, n = 16) 
were by proxy – through the mothers (in all instances) of a CWH, and the remaining third (n 
= 8) were conducted directly with PWH. The mean age of CWH was 6.25 ± 4.31 years (range 
1‐14). The mean age of PWH was 36.8 ± 13.7 years (range 16‐56). 
 
More than half of participants (58.3%, n = 14) had haemophilia A (Table 1). Overall, 7 (29%) 
of participants were treated with an EHL product at P1 (5 with EHL‐FVIII and 2 with EHL‐FIX) 
and 17 (71%) were treated with an EHL product at P2 (15 with EHL‐FII and 2 with EHL‐FIX). 
The recruiting criteria for the study were participants who were about to switch to EHL 
therapy; seven individuals had already switched 1‐10 weeks pre interview, five of these 
were parents of children with haemophilia who had switched 4‐10 weeks prior to interview. 
It also became apparent that one participant was using a non‐Fc fusion protein EHL, this was 
more than half‐way through the P1 interview. The study team decided pragmatically that 
these interviews would be included as the parents would have good recall of their switching 
decisions and the patient interview had generated new data that was relevant to using EHL 
therapy per‐se. 
 
The themes that emerged from the interviews are discussed here: 
 
 
 
3.1.1   Expectations 
 
All patients being considered for EHL treatment in the UK were required to undergo 
pharmacokinetic (PK) assessment and dosing; this was done as part of routine clinical care 
and was not part of   the HOPE study. Having undergone PK assessment participants 
expected that EHL products would require less frequent dosing, less disruption and less 
demand on veins or central venous access de‐ vices (CVADs). Some hoped they would offer 
better protection and therefore would experience fewer bleeds. There was initial 
uncertainty about future benefits because dose frequency could not be predicted at the 
pre/switch time point of P1. 
 
 
 
3.1.2   Experiences 
 
In all, 17 participants were using EHLs at P2. The majority of sentiments expressed towards 
EHL were positive; however, a small number of participants also expressed mixed 
sentiments about aspects of their treatment. 
 
Seventy‐three per cent of participants were positive about EHL products stating less 
disruption, fewer treatment administrations, fewer bleeds, feeling more protected, 
improved mental health and improved sense of well‐being. This meant reduced dosing; 
reduced burden of venous access; greater benefits in families with more than one child 
using an EHL; and greater flexibility about staying away from home. Participants felt that 
EHLs had lived up to their expectations and in one case had exceeded them. Several 
reserved judgement, saying it was too soon to comment or they were uncertain about the 
longer term suitability of their treatment. 
 
Neutral experiences were reported by 20%: this included expectations not being met, with 
little change in protection against bleeds (based on trough levels), dose frequency or 
disruption. A small number of participants (7%) reported negative experiences including a 
lack of confidence in an unfamiliar medicine. 
 
 
 
TABLE 1 Characteristics of participants, treatment and interviews completed 
 
 
Treatment Interview 
 
 
 
Participanta and number Ageb (y) Haemophilia Inhibitor historyc P1 P2 P1
 P2 
H1 Carer 12 A Previous Elocta Elocta ● ● 
H2d PWH 44 B  Idelvion Idelvion ● ● 
H3 PWH 44 A  Refacto Elocta ● ● 
H4 PWH 36 A  Advate Elocta ● ● 
H5 PWH 33 A  Refacto Refacto ● ● 
H6 Carer 2 A Previous Advate Advate ● ● 
H7 Carer 12 A  Refacto Refacto ● ● 
H8 Carer 2.5 A  Advate Elocta ● ● 
H9 Carer 1.5 A  Elocta Elocta ● ● 
H10 Carer 5 A  Advate Elocta ● ● 
H11 Carer 1 A  Elocta Elocta ● ● 
H12 Carer 8 A Previous Advate Elocta ● ● 
H13 Carer 14 A  Refacto Elocta ● ● 
H14 Carer 6 A  Refacto Refacto ● ● 
H15 PWH 46 A  Advate No P2 ● ‐ 
H16e Carer 3 A  Elocta No P2 ● ‐ 
H17 PWH 16 B  Alprolix Alprolix ● ● 
H18e Carer 3 A Current Advate No P2 ● ‐ 
H19 Carer 10 A  Elocta Elocta ● ● 
H20 Carer 1 A Previous Advate Elocta ● ● 
H21 PWH 56 A  Refacto Elocta ● ● 
H22 PWH 19 A  No P1 Elocta ‐ ● 
H23 Carer 5 A  Refacto No P2 ● ‐ 
H24 Carer 9 A  No P1 Elocta ‐ ● 
H25 Carer 5 A Previous No P1 Elocta ‐ ● 
Abbreviation: PWH, person with haemophilia. 
 
A Person who was interviewed. 
 
B Age of PwH at time of interview. 
 
C Inhibitor history at PI – no patients developed inhibitors during the study. 
 
dPatient H2 confirmed his eligibility in screening but his treatment (Idelvion) emerged only in interviews; although not on a Sobi product he was 
not withdrawn as analysis revealed many interesting comments. 
 
ePatient H18 was withdrawn as he switched to emicizumab. 
 
 
 
 
Most participants did not fully understand the term ‘pharmacokinetics’ or their trough 
levels and thus the rationale for the new infusion frequency. Of those whose experiences 
were neutral or negative, two were unsure whether they wanted to continue to use EHL 
products. 
 
 
 
3.1.3 Treatment frequency 
 
Many who had switched to EHLs had experienced reductions in dose frequency. At P1, this 
was the source of some uncertainty as participants refined and adapted to a new treatment 
pattern. Others reported (at P1 or P2) no change in dose but felt they were better covered 
because factor levels were higher than with traditional factors. The reduction in number of 
treatments needed per week was seen as a positive outcome of using EHL therapy – even if 
this was ‘only’ one infusion less per week. 
 
  
 
3.1.4  Adherence 
 
Participants were aware that treatment adherence is a concern for clinicians and most 
reported adhering to their treatment plan and never or rarely missing doses. Most 
administered their EHL treatment in the morning, though there was greater flexibility at 
week‐ ends. The main reason cited for missing a dose was work, tiredness or being too busy 
with other tasks. This was most noticeable in parent/carers. 
 
In children, age was an important factor in the decision to tailor treatment. Most parents of 
very young children saw no need to tailor dosage because they perceived a low risk of 
trauma. School‐ age children tended to be very active, and in some cases, additional 
treatments were given before an activity but many parents managed risk by tailoring both 
activities and factor administration. There was little evidence overall that PWH avoided 
activities though not all tailored their treatment to manage bleed risk. 
 
When initiating EHL treatment, participants had to adjust treatment routines, which made 
adherence difficult for some. Some felt that haemophilia centres exerted pressure on them 
to adhere: they knew the products were expensive and that access was controlled and some 
stated that the EHL would be withdrawn if they did not follow the treatment plan stating 
that in the past it may have been possible to conceal a missed dose, but this was no longer 
an option because treatment was now more closely monitored. 
 
Home treatment with EHLs is monitored with the Haemtrack app, which logs the date and 
time of dose administration. The re‐ cord is scrutinized by clinicians, who can identify 
missed doses. Some participants felt under pressure to use Haemtrack but most were 
positive: they considered it convenient and easy to use. A minority of users reported 
technical problems with updates and reliability and improvements were suggested. 
Participants reported being contacted by a clinician requesting an explanation when their 
Haemtrack data revealed missed doses; some reported being told that they would not have 
bleeds if they adhered to the treatment plan. One parent reported making a special effort 
with data recording adherence to secure treatment with an EHL; however, her child still did 
not receive EHL therapy. 
 
 
 
3.1.5   Bleeds 
 
This study was not designed to quantify the effect of EHLs on bleeding frequency. At P1, 
several participants reported 1‐2 bleeds per month; some participants reported at P2 that 
their bleeding frequency had decreased after starting EHL treatment. Participants tended to 
manage a bleed with additional doses of factor even when this was not part of their 
treatment plan; clinical advice was sought when this and other measures had failed. Some 
participants felt that treatment with an EHL made their decisions about managing bleeds 
more complex, including comments about timing of repeat doses during the early stages of 
EHL use. 
 
 
 
3.1.6   Switching decision 
 
The discussion about switching to an EHL was most likely to be, but not exclusively, initiated 
by a clinician. The main barriers to switching from the participants’ perspective were a lack 
of detailed information about EHL products and not wanting to change an established and 
effective treatment. One mother reported being at the point of switching for her 6‐year‐old 
son, but had concerns about potential side effects of a new molecule (inhibitor and cancer 
risks) and decided to wait until there was more data on use in children. Some participants 
suggested that EHLs were not available in some geo‐ graphical areas, one stated that their 
hospital had offered EHL but was ‘still tied up in a contract for his “old” factor and he 
wouldn't be able to switch for a further 6 months’ or that some people were not eligible for 
treatment switching. One parent had initially been reluctant to join a clinical trial and the 
haemophilia centre never broached the possibility again; so the child was unable to switch 
until the product was commercially available. A switch was delayed for one child in the hope 
that an inhibitor would be eradicated. 
 
More concerns were expressed at P1, when some participants had just started using an EHL, 
than at P2. The reduced treatment frequency prompted concerns that ‘cover’ would be 
insufficient, with one participant describing previous daily dosing as a ‘safety blanket’. Some 
were concerned about the possible unidentified risks of a new and unfamiliar treatment. 
The different pharmacokinetic properties of EHLs raised perceived concerns at P1, including 
shorter half‐life than suggested by the product literature and misunderstanding about 
metabolism of EHLs. 
 
Extended half‐lifes are more expensive than SHL factors in the UK, and NHS providers have 
been selective who is eligible for treatment, effectively restricting access to some patients 
or delaying the local introduction of EHLs.2 Though there was understanding about the 
pressure on the NHS to manage resources, some participants and carers were sceptical that 
access to EHLs was determined on primarily clinical grounds, suspecting that limiting cost 
was the main determinant: the conditions imposed on EHL treatment were perceived to be 
designed to ensure ‘cost neutrality’ – that is to prevent costs increasing. Once prescribed, 
continued access to treatment with EHLs is generally conditional on adherence to an agreed 
treatment plan and monitoring with Haemtrack. 
 
 
 
 
 
4 DISCUSSION 
 
 
 
Our interview methodology involved reporting things to participants that others had said 
(eg ‘we have heard XYZ – has that ever happened to you?’) This is a recognized qualitative 
interviewing technique, but risks leading discussion. The interviewers were aware of this 
and were cautious with wording of questions and amended questions frequently 
throughout the interview phase of the study, which continued until we reached a point of 
data saturation where no new discussions could be coded against a theme or topic. This 
enables us to report the experience of this study cohort. 
 
Patient experience is an important aspect of measuring the effectiveness of NHS health 
care11 but the outcomes usually collected are quantitative in nature, through clinical trials 
or through quantitative measures more generally (number of joint bleeds, number of 
infusions, amount of treatment used) rather than based on qualitative assessment. We have 
used a qualitative research methodology involving semi‐structured interviews with a 
longitudinal element to explore and describe patient expectation and experience around 
using EHL products in routine clinical care, adding real‐world data to clinical trial experience 
of these products. These participants were ‘early adopters’ of EHL therapy in a non‐trial 
situation; they may have hoped for greater benefit from switching early based on perceived 
benefit of their peers in clinical trials. Patients switching to EHL treatments believe these 
products will result in fewer infusions and less disruption of everyday life, leaving them 
feeling more protected with fewer bleeds and increased activity levels, as well as enhanced 
well‐being and mental health. This was also described in a recent survey of over 1000 
patients/parents.12 
 
Patient satisfaction is recognized to be an important determinant of treatment 
adherence.13 Most participants who were receiving EHL treatments in our study were 
positive about it and intended to continue with it. The majority of participants experienced 
reduced frequency of treatment which meant that their lifestyles were less disrupted or less 
dominated by haemophilia, with less perceived stress on overused veins. Some were able to 
dispense with CVADs, something that has been demonstrated to reduce caregiver bur‐ 
den.14 Even in those cases where there was not reduced frequency of treatment after 
switching to EHL treatments, there were often other perceived benefits such as higher 
troughs with greater levels of protection and fewer bleeds. 
 
A number of participants wanted more information about EHL treatments – in some cases 
about its availability in their area, or regarding research about outcomes over the longer 
term. There may be a case for hospitals and haemophilia centres, perhaps in conjunction 
with providers of EHL treatments, to evaluate their current pro‐ vision of information about 
EHL treatments and to consider whether any changes or improvements are appropriate. 
This was particularly apparent in discussing understanding of PK (which all participants had 
undergone as part of the clinical switching programme); there was a clear lack of knowledge 
about factor levels, timing of infusions and treatment for bleeding episodes. This is an area 
that requires additional patient/carer education. 
 
Some participants were hoping to switch from standard half‐ life products at P1 but had still 
not done so at P2, because of cost or because they felt, haemophilia centres seemed 
reluctant to make the change. The decision to offer EHL treatment should not be on a 
simplistic basis of a cost comparison with non‐EHL treatments. Our analysis suggests that 
there are distinct advantages to EHL treatment, such as feelings of better protection and 
some evidence of greater activity levels, reduced bleeds and pain. The HOPE study was a 
qualitative study, which explored and described experiences of PWH using EHL treatments – 
a causal relation‐ ship between EHL treatment and these outcomes is not claimed. 
Nevertheless, there is certainly a case for a more rigorous study designed to assess whether 
there are such relationships, and if so, then clearly ‘value’ should be attributed to these 
benefits when making the decision to offer EHL treatment. 
 
There seemed to be considerable barriers to PWH obtaining or staying on EHL treatment, 
which relate to perceived cost or ‘rationing’ of treatment by haemophilia centres. This study 
was con‐ ducted during a period of historically high levels of financial stress within NHS 
funding, particularly when compared to other western European countries. There has also 
been an apparent resurgence of the postcode lottery as commissioning has become 
increasingly local, discretionary and therefore variable following the Health and Social Care 
Act 2012.15 This was reported by two participants, from the same geographical region, who 
reported being unable to switch due to contracting/budgetary issues. Haemophilia care in 
the UK is commissioned through the specialized commissioning route, and the availability of 
factor products is subject to competitive tendering, which can place limits to the range of 
products clinicians are able to offer patients. Nevertheless, it is important for clinicians to 
remember that the value of a treatment is not represented by its cost alone. 
 
Clinicians should be careful not to place undue pressure on PWH in terms of creating a 
perception that anything less than complete adherence may result in the withdrawal of a 
treatment. In some cases, the need of haemophilia centres to gather evidence about cost‐
effectiveness appeared to result in strong pressure on PWH to adhere very strictly to the 
agreed treatment plan (monitored remotely through Haemtrack), at the perceived risk of 
having the treatment withdrawn. This meant that the HOPE study participants felt unable to 
tailor their own treatment around ‘risky’ activities as they had done when using SHL factors; 
this led to anxiety about bleeding risk and limited some activities. There needs to be more 
and better information about EHL treatments, including pharmacokinetics and individual 
treatment plans. This study was undertaken as Fc fusion protein EHL factors be‐ came 
commercially available in the UK. Any patient who switched had undergone PK assessment 
as part of the switching programme and may have had different views about his new 
therapy based on this knowledge. The numbers are too small to compare between parent 
and patient experience or between haemophilia A and haemophilia B where the benefits of 
once weekly prophylaxis might have been expected to be greater. We believe there is a 
need for a comparative study designed to adequately capture real‐world haemophilia 
treatment burden and to demonstrate the potential bene‐ fit that can be attributed to EHL 
products. Such a study would add further evidence from real‐world data to support that 
obtained in quality of life outcomes in clinical trials.16,17 This would help to ensure that the 
patient voice is heard in shared decision‐making about therapeutic options in keeping with 
the ‘no decision about me without me’ mantra in the NHS consultation.15 
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